What the trial was testing
The SHINE enrolled 523 patients with mantle cell lymphoma. The study was sponsored by Janssen Research & Development and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
80.6 vs. 52.9 months — how long the cancer stayed under control with vs. without ibrutinib.
New England Journal of Medicine · 2022 · NCT01776840
These findings — that median time before mantle cell lymphoma progressed with vs. without first-line ibrutinib — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 523 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with mantle cell lymphoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Ibrutinib (Imbruvica) is FDA-approved for mantle cell lymphoma and available now. SHINE shows that adding it upfront to first-line treatment buys an extra ~2 years before the cancer comes back — but doesn't make people live longer overall. Ask your oncologist whether the trade-off (more time before recurrence vs. heavier side effects, no survival gain) makes sense for your situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open mantle cell lymphoma trials
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.